Long-term Efficacy of 2 Year WHO Multiple Drug Therapy (MDT) in Multibacillary (MB) Leprosy Patients

International Journal of Leprosy and Other Mycobacterial Diseases

Volumn 71, Issue 4, 2003, Pages 308-319

  Cellona, Roland V ^a   Balagon, Maria V F ^b   Dela Cruz, Eduardo C ^b   Burgos, Jasmin A ^b   Abalos, Rodolfo M ^b   Walsh, Gerald P ^b   Topolski, Richard ^b   Gelber, Robert H ^b   Walsh, Douglas S ^b  

^a Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILD; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOOT PAD; HISTOLOGY; HUMAN; LEPROSY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NONHUMAN; RELAPSE; SKIN BIOPSY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM LEPRAE; PHILIPPINES; RECURRENCE; TIME FACTORS; WORLD HEALTH ORGANIZATION;

EID: 1242293831     PISSN: 0148916X     EISSN: None     Source Type: Journal    
DOI: 10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2     Document Type: Article

References (58)

1. ALTMAN, D. G. Practical Statistics for Medical Research. New York: Chapman and Hall, 1991.
2. ANONYMOUS. Relapse following fixed duration treatment for multibacillary leprosy. Wkly. Epidemiol. Rec. 69 (1994) 301-302.
3. ANONYMOUS. Subcommittee on clinical trials of the chemotherapy of leprosy (THELEP). Scientific working group of the UNDP/World Bank/ WHO special program for research and training in tropical diseases. Lepr. Rev. 58 (1987) 325-327.
4. BALAGON, M. V., CELLONA, R. V., FAJARDO, T. T., JR., ABALOS, R. M., WALSH, D. S., VILLAHERMOSA, L. G., TAN, E. V., DELA CRUZ, E. C., and WALSH, G. P. Detection of new leprosy cases at a walk-in skin clinic in Cebu City, Philippines, highlights surveillance. Int. J. Dermatol. 38 (1999) 796-797.
5. BANDERA, A., GORI, A., CATOZZI, L., DEGLI ESPOSTI, A., MARCHETTI, G., MOLTENI, C., FARRARIO, G., CODESCASA, L., PENATI, V., MATTEELI, A., and FRANZETTI, F. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J. Clin. Microbiol. 339 (2001) 2213-2218.
6. BAOHONG, J. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr. Rev. 72 (2001) 3-7.
7. BECX-BLEUMINK, M. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Int. J. Lepr. Other Mycobact. Dis. 60 (1992) 421-435.
8. BECX-BLEUMINK, M. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int. J. Lepr. Other Mycobact. Dis. 60 (1992) 161-172.
9. BENATOR, D., BHATTACHARYA, M., BOZEMAN, L., BURMAN, W., CANTAZARO, A., CHAISSON, R., GORDIN, F., HORSBURGH, C. R., HORTON, J., KHAN, A., LAHART, C., METCHOCK, B., PACHUCKI, C., STANTON, L., VERNON, A., VILLARINO, M. E., WANG, Y. C., WEINER, M., WEIS, S., and TUBERCULOSIS TRIALS CONSORTIUM. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 360(9332) (2002) 528-534.
10. BLUMBERG, H. M., BURMAN, W. J., CHAISSON, R. E., DALEY, C. L., ETKIND, S. C., FRIEDMAN, L. N., FUJIWARA, P., GRZEMSKA, M., HOPEWELL, P. C., ISEMAN, M. D., JASMER, R. M., KOPPAKA, V., MENZIES, R. I., O'BRIEN, R. J., REVES, R. R., REICHMAN, L. B., SIMONE, P. M., STARKE, J. R., VERNON, A. A., AMERICAN THORACIC SOCIETY, CENTERS FOR DISEASE CONTROL AND PREVENTION, and THE INFECTIOUS DISEASES SOCIETY. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167(4) (2003) 603-662.
11. BRYCESON, A., and PEALTZGRAF, R. E. In: Leprosy, 3rd ed. Edinburgh: Churchill Livingstone, 1990, pp. 134-176.
12. CHEN, X. S., LI, W. Z., JIANG, C., and YE, G. Y. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy. Int. J. Lepr. Other Mycobact. Dis. 67 (1999) 379-387.
13. CONSIGNY, S., BENTOUCHA, A., BONNAFOUS, P., GROSSET, J., and JI, B. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob. Agents Chemother. 44 (2000) 2919-2921.
14. DASANANJALI, K. Relapse of leprosy after multidrug therapy. J. Med. Assoc. Thai. 79 (1996) 635-639.
15. DASANANJALI, K., SCHREUDER, P. A., and PIRAYAVARAPORN, C. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996. Int. J. Lepr. Other Mycobact. Dis. 65 (1997) 28-36.
16. DELA CRUZ, E., CELLONA, R. V., BALAGON, M. V., VILLAHERMOSA, L. G., FAJARDO, T. T., JR., ABALOS, R. M., TAN, E. V., and WALSH, G. P. Primary dapsone resistance in Cebu, The Philippines; cause for concern. Int. J. Lepr. Other Mycobact. Dis. 64 (1996) 253-256.
17. EDITORIAL. Leprosy beyond the year 2000 [editorial]. Lancet 350 (1997) 1717.
18. Fox, W., ELLARD, G. A., and MITCHISON, D. A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3 (1999) S231-279.
19. GEBRE, S., SAUNDERSON, P., and BYASS, P. Relapses after fixed duration multiple drug therapy: the AMFES cohort. Lepr. Rev. 71 (2000) 325-331.
20. GELBER, R. Our experience with another multidrug therapy regimen for leprosy. Int. J. Lepr. Other Mycobact. Dis. 66 (1998) 9a-10a.
21. GELBER, R. H. Activity of minocycline in Mycobacterium leprae-infected mice. J. Infect. Dis. 156 (1987) 236-239.
22. GELBER, R. H. Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Eur. J. Clin. Microbiol. Infect. Dis. 13 (1994) 942-952.
23. GELBER, R. H., WATERS, M. F., PEARSON, J. M., MCDOUGALL, A. C., and REES, R. J. Persisting M. leprae after dapsone and dapsone plus rifampicin treatment of lepromatous leprosy. Int. J. Lepr. Other Mycob. Dis. 44 (1976) 5480549.
24. GIRDHAR, B. K., GIRDHAR, A., and KUMAR, A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr. Rev. 71 (2000) 144-153.
25. GRANGE, J. M. The mystery of the mycobacterial 'persistor.' Tuber. Lung Dis. 73 (1992) 249-251.
26. GROATHOUSE, N., RIVOIRE, B., CHO, S., KIM, H., LEE, H., BRENNAN, P., and VISSA, V. Polymorphisms in short tandem repeat sequences of Mycobacterium leprae allow for the epidemiological characterization of strains. (In press).
27. GUINTO, R. S., CELLONA, R. V., FAJARDO, T. T., and DE LA CRUZ, E. C. Primary dapsone-resistant leprosy in Cebu, Philippines. Int. J. Lepr. Other Mycobact. Dis. 49 (1981) 427-430.
28. JAMET, P., and JI, B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Int. J. Lepr. Other Mycobact. Dis. 62 (1994) 62.
29. JAMET, P., and JI, B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int. J. Lepr. Other Mycobact. Dis. 63 (1995) 195-201.
30. JAMET, P., and JI, B. Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group. Int. J. Lepr. Other Mycobact. Dis. 60 (1992) 525-535.
31. JESUDASAN, K., VIJAYAKUMARAN, P., MANIMOZHI, N., JEYARAJAN, T., and RAO, P. S. Absence of relapse within 4 years among 34 multibacillary patients with high BIs treated for 2 years with MDT. Int. J. Lepr. Other Mycobact. Dis. 64 (1996) 133-135.
32. JESUDASAN, K., VIJAYAKUMARAN, P., MANIMOZHI, N., RAO, P. S., and SAMUEL, P. Effectiveness of MDT in multibacillary leprosy. Int. J. Lepr. Other Mycobact. Dis. 64 (1996) 128-132.
33. JI, B. Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks. Int. J. Lepr. Other Mycobact. Dis. 66 (1998) 391-392.
34. JI, B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr. Rev. 69 (1998) 106-109.
35. LEE, E. T. In: Statistical Methods, for Survival Analysis Data. 2nd ed. New York: Wiley, 1992, pp. 109-112.
36. LI, H. Y., Hu, L. F., HUANG, W. B., LIU, G. C., YUAN, L. C., JIN, Z., LI, X., LI, J. L., and YANG, Z. M. Risk of relapse in leprosy after fixed-duration multidrug therapy. Int. J. Lepr. Other Mycobact. Dis. 65 (1997) 238-245.
37. LI, H. Y., HU, L. F., WU, P. W., LUO, J. S., and LIU, X. M. Fixed-duration multidrug therapy in multibacillary leprosy. Int. J. Lepr. Other Mycobact. Dis. 65 (1997) 230-237.
38. LI, H. Y., RAN, S. P., WENG, X. M., LI, T. G., DENG, X. H., and LI, F. T. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy. Indian J. Lepr. 73 (2001) 1-10.
39. LOCKWOOD, D. N. Leprosy elimination - a virtual phenomenon or a reality? BMJ 324 (2002) 1516-1518.
40. MATSUOKA, M., MAEDA, S., KAI, M., NAKATA, N., CHAE, G. T., GILLIS, T. P., KOBAYASHI, K., IZUMI, S., and KASHIWABARA, Y. Mycobacterium leprae typing by genomic diversity and global distribution of genotypes. Int. J. Lepr. Other Mycobact. Dis. 68 (2000) 121-128.
41. PATTYN, S., and GRILLONE, S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr. Rev. 73 (2002) 245-247.
42. PATTYN, S. R., DOCKX, P., ROLLIER, M. T., ROLLIER, R., and SAERENS, E. J. Mycobacterium leprae persisters after treatment with dapsone and rifampicin. Int. J. Lepr. Other Mycobact. Dis. 44 (1976) 154-158.
43. PATTYN, S. R., GROENEN, G., JANSSENS, L., KUYKENS, L., and MPUTU, L. B. Treatment of multibacillary leprosy with a regimen of 13 weeks duration. Lepr. Rev. 63 (1992) 41-46.
44. RIDLEY, D. S., and JOPLING, W. H. Classification of leprosy according to immunity. A five-group system. Int. J. Lepr. Other Mycobact. Dis. 34 (1966) 255-273.
45. SCHREUDER, P. A. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study. Int. J. Lepr. Other Mycobact. Dis. 66 (1998) 149-158.
46. SEHGAL, V. N., and JOGINDER. Slit-skin smear in leprosy. Int. J. Dermatol. 29 (1990) 9-16.
47. SHAW, I. N., NATRAJAN, M. M., RAO, G. S., JESUDASAN, K., CHRISTIAN, M., and KAVITHA, M. Long-term follow-up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years. Int. J. Lepr. Other Mycobact. Dis. 68 (2000) 405-409.
48. SHEPARD, C. C. The experimental disease that follows the injection of human leprosy into footpads of mice. J. Exp. Med. 112 (1960) 445-454.
49. SHEPARD, C. C., and MCRAE, D. H. A method for counting acid-fast bacteria. Int. J. Lepr. Other Mycob. Dis. 36 (1968) 78-82.
50. SHETTY, V. P., SUCHITRA K., UPLEKAR M. W., and ANTIA, N. H. Persistence of Mycobacterium leprae in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients. Lepr. Rev. 63 (1992) 329-336.
51. SHIN, Y. C., LEE, H., WALSH, G. P., KIM, J. D., and CHO, S. N. Variable numbers of TTC repeats in Mycobacterium leprae DNA from leprosy patients and use in strain differentiation. J. Clin. Microbiol. 38 (2000) 4535-4538.
52. SMALL, P. M., SHAFER, R. W., HOPEWELL, P. C., SINGH, S. P., MURPHY, M. J., DESMOND, E., SIERRA, M. F., and SCHOOLNIK, G. K. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 328 (1993) 1137-1144.
53. SOARES, D. J., NEUPANE K., and BRITTON, W. J. Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy. Lepr. Rev. 66 (1995) 210-213.
54. SUITE, M. Relapse rates following leprosy multidrug therapy. West Indian Med. J. 49 (2000) 210-211.
55. SUNEETHA, S., and REDDY, R. Histological resolution and bacterial clearance with pulse ROM therapy in borderline lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis. 69 (2001) 53-54.
56. THANGARAJ, R. H., and YAWALKAR S. J. Leprosy for Medical Practioners and Medical Workers. 3rd ed. Basel: CIBA-GEIGY Limited, 1988.
57. WHO. Risk of Relapse in Leprosy. Geneva: World Health Organization, 1994.
58. WHO STUDY GROUP. Chemotherapy of Leprosy for Control Programs. Geneva: World Health Organization, 1982. Tech. Rep. Ser. 675.